Observational studyMedicine2025

Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine.

Nijat Khanmammadov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.